Erratum to: Linagliptin: a review of its use in the management of type 2 diabetes mellitus

1 Erratum to: Drugs (2012) 72:1793–1824 DOI 10.2165/11209570-000000000-00000

Page 1804, column 1, section 5.3.1, paragraph 2, which previously read:

“Significantly^[12] or numerically^[11,54] more patients in the linagliptin than in the placebo groups achieved an HbA_1c level of ≤7.0% (table IV)^[11,12] or <6.5% (10% vs 2%; OR 5.5; p < 0.0016),^[12] a reduction in HbA_1c of ≥0.5% (table IV)^[12,54] or required rescue therapy (8% vs 19%; OR 0.28; p = 0.0001).^[12]”

Should read:

“Significantly^[12] or numerically^[11,54] more patients in the linagliptin than in the placebo groups achieved an HbA_1c level of ≤7.0% (table IV)^[11,12] or <6.5% (10% vs 2%; OR 5.5; p < 0.0016)^[12] or a reduction in HbA_1c of ≥0.5% (table IV),^[12,54] and significantly fewer linagliptin than placebo recipients required rescue therapy (8% vs 19%; OR 0.28; p = 0.0001).^[12]”